NCT02747953View on ClinicalTrials.gov

Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib

PHASE2CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

December 31, 2014

Study Completion Date

November 30, 2016

Conditions
Non-small Cell Lung Cancer
Interventions
DRUG

Gilotrif

50 mg with an option to reduce the dose to 40mg or 30 mg once a day Continuous daily dosing, one course consists of 28 days. Patients are eligible for repeated treatment courses in the absence of disease progression and undue toxicity.

All Listed Sponsors
lead

Samsung Medical Center

OTHER

NCT02747953 - Gilotrif (Afatinib) in Advanced Non-Small Cell Lung Cancer Patients Pre-treated With Erlotinib or Gefitinib | Biotech Hunter | Biotech Hunter